Introduction
============

Nasopharyngeal carcinoma (NPC), one of the few head and neck malignancies prone to distant metastasis, is prevalent in Southern China, Southeast Asia, North Africa, the Middle East, and Alaska [@B1], [@B2]. In previous reports, 7.7%-20.3% patients had metastases at presentation, with the bones, lung, and liver as the most commonly affected sites [@B3]-[@B12]. Aggressive loco-regional radiotherapy with or without chemotherapy is the recommended strategy for non-metastatic NPCs, and the long-term overall survival rate in these cases exceeds 80% [@B13], [@B14]. However, systemic palliative chemotherapy is the standard treatment for patients with metastasis, and the 1-year overall survival rate is only about 50% [@B1].

Distant metastasis is one of the most critical factors guiding treatment decisions in oncology and supposed to be diagnosed effectively [@B15]. Conventional imaging tests to detect metastasis, including ultrasonography, skeletal scintigraphy, and magnetic resonance imaging (MRI), require multiple tests and their accuracy is not much satisfactory [@B16], [@B17]. Integrated ^18^F-fluorodeoxyglucose (^18^F-FDG) positron emission tomography/computed tomography (PET/CT) can detect the increase in glucose metabolism in tumor cells and offer anatomical details at the same time. Moreover, it enables whole-body examination in a single test [@B18]. However, disadvantages of PET/CT, including exposure of patients to ionizing radiation, requirement for a cyclotron, and high costs, affect its wide application [@B19].

Conventional work-ups (CWUs; that is, skeletal scintigraphy, chest X-ray examination, and liver ultrasound) are widely used to detect metastasis in NPC, especially in developing countries, because of their low cost and accessibility [@B1], [@B20]. A large prospective study reported that CWUs presented equal effectiveness as PET/CT for patients who have both N0-1 classification and Epstein-Barr virus (EBV)-DNA less than 4000 copies/mL [@B9]. A previous meta-analysis on the diagnostic performance of PET/CT in newly diagnosed NPC merely enrolled a small sample size of 385 patients [@B21]. Moreover, it did not compare the diagnostic performance of PET/CT and CWUs.

Therefore, the optimal modality of choice on the diagnostic performance of detecting distant metastasis in primary NPC during initial staging still requires thorough investigation. We conducted this study to individually assess the overall value of ^18^F-FDG PET/CT and CWUs, and to perform a head-to-head comparison between the two modalities.

Materials and Methods
=====================

Identification and eligibility of relevant studies
--------------------------------------------------

A prospective protocol was initially planned according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) [@B22]. We systemically searched in MEDLINE, EMBASE and Cochrane Library for eligible articles without restrictions to language or region; additionally, we searched in the Chinese Biomedical Disc (CBMdisc) database for Chinese articles (last updated on October 3, 2016). The search algorithm was based on the following terms for all possible combinations: (1) fluorodeoxyglucose, FDG, positron emission tomography/computed tomography, or PET/CT; (2) conventional work-ups, CWUs; (3) nasopharyngeal carcinoma, nasopharyngeal cancer.

After the initial screening of the title and abstract of retrieved literatures, the full text of relevant articles was independently assessed by two investigators for inclusion (Y.Z. and L.P.) and any disagreements were resolved by consensus. The references in relevant articles were then manually screened for additional studies. The inclusion criteria were as follows: (a) ^18^F-FDG PET/CT and CWUs were used for detecting whole-body distant metastasis in NPC; (b) Per-patient statistics including true positive, false positive, true negative, and false negative number were reported; (c) Among reports that pertained to overlapping patient cohorts, we retained the largest study to avoid duplication of information; (d) At least one of the following strategies was used as the reference standard: biopsy, imaging or clinical follow-up.

We excluded studies based on the following criteria: (a) Studies enrolled patients with residual/recurrent NPC; (b) Studies enrolled mixed patients with untreated and residual/recurrent disease, if relevant data regarding the untreated patients could not be obtained; (c) Studies enrolled patients with no evidence of distant metastasis on CWUs; (d) Case reports, conference abstracts and reviews.

Quality assessment and data extraction
--------------------------------------

Two investigators (Y.Z. and L.P.) independently evaluated the methodological quality of all included studies using the Quality Assessment tool for Diagnostic Accuracy Studies version-II (QUADAS-II) [@B23]. It consists of four key domains covering patient selection, index test, reference standard, and flow and timing. Each domain was assessed in terms of risk of bias and the first three were assessed in terms of concerns regarding applicability. If a study had ≥ four items of low risk/concern, it was considered to be of high-quality. Moreover, signalling questions were used to help reach judgements on the domains of risk of bias.

In addition, for each report, we recorded the author names, year of publication, time range, country or region, sample size, technical parameters, interpreters, criteria defining positive PET/CT results, reference standards, follow-up time and so on. To assess the technical quality of PET/CT, we referred to the guidelines of the Society of Nuclear Medicine [@B24] and consulted two nuclear medicine physicians (X.Z. and X.P.L.) experienced in PET/CT imaging.

The same investigators extracted data from eligible studies independently by using a standardized data extraction form, and any disagreements were resolved by consensus. The investigators were not blinded to information regarding the journal name, authors, or affiliations, since this was unnecessary [@B25]. For each study, we recorded the number of true positive, false positive, true negative, and false negative findings of each modality in diagnosing distant metastasis. We used all available information, including findings per patient and per site (bones, lung, and liver).

Statistical analysis
--------------------

We calculated *kappa* coefficient to evaluate the agreement between investigators regarding their answers for signalling questions; *P* \< 0.05 indicated a good inter-rater reliability [@B26]. We explored the threshold effect inducing heterogeneity using Spearman correlation coeffecient; *P* \< 0.05 suggested presence of threshold effect [@B27]. In order to detect the heterogeneity due to sources other than threshold effect, we examined sensitivity, specificity, and negative and positive likelihood ratios (LR- and LR+, respectively) using Cochran-Q and Chi-square (*χ^2^*) test with the significance set at *P* \< 0.05. I-square (*I^2^*) statistic was also calculated to measure heterogeneities; *I^2^*-value \> 25%, 50% or 75% was considered to have mild, moderate or substantial heterogeneity [@B28].

We constructed summary receiver operating characteristic (SROC) curves to quantitatively summarize study results. A symmetric SROC curve was performed in the DerSimonian-Laird model when regression coefficient-*b,* the difference between the slope of the fitted regression line and zero, was non-significant (*P* \> 0.05) [@B27]. We calculated pooled sensitivity, specificity, LR-, LR+, area under the curve (AUC), and Q\* index (the maximum joint sensitivity and specificity) for each modality. The necessary precondition to demonstrate forest plots of those outcomes is that no substantial heterogeneity exists [@B27]. LR- is defined as the ratio of (1 - sensitivity) over specificity, whereas LR+ is defined as the ratio of sensitivity over (1 - specificity). Although there is no absolute cutoff, a good diagnostic test would generally have LR+ \> 5.0 and LR- \< 0.2. The maximum joint sensitivity and specificity was defined as the point on the SROC curve that is intersected by a diagonal line that runs from the top left corner to the bottom right corner of the ROC diagram; this could be calculated by using the formula Q\* = (1+e^‑A/2^)^-1^, where A is the summary log odds ratio (sensitivity/1 - specificity). Z test was used to compare all the pooled outcomes between modalities.

The methodological quality summary of included studies was performed using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK). Potential publication bias was investigated using Deeks\' funnel plot by Stata software 12.0 (StataCorp, College Station, TX, USA); *P* \< 0.10 indicated a high likelihood of publication bias [@B29]. All statistical analyses and figures were produced using Meta-Disc version 1.4 (Ramóny Cajal Hospital, Madrid, Spain) [@B30].

Results
=======

Study identification and description
------------------------------------

After the rounds of selection presented in Figure [1](#F1){ref-type="fig"}, ten studies enrolling 1774 patients were included in our study. Table [1](#T1){ref-type="table"} presents the characteristics of the eligible studies. All studies were performed in Asia and enrolled patients with any stages, of which, six studies were published in English [@B3]-[@B7], [@B9] and four were in Chinese with English abstracts [@B8], [@B10]-[@B12]. Five studies were prospective [@B4]-[@B7], [@B9] while another five studies were retrospective [@B3], [@B8], [@B10]-[@B12]. One study compared CWUs with standalone ^18^F-FDG PET [@B4]; the remaining nine studies compared PET/CT with different diagnostic modalities, such as CWUs, CT, whole-body MRI, and CT+skeletal scintigraphy [@B3], [@B5]-[@B12].

The technical parameters of nine studies employing PET/CT are shown in Table [2](#T2){ref-type="table"}. Generally, these studies followed most of the guidelines for performing PET/CT imaging [@B24]. Four studies implemented a comparison of PET/CT and CWUs on both patient and site basis [@B5], [@B6], [@B9], [@B10]. All studies used the visual interpretation to define positive PET/CT results; four of them used semi-quantitive criteria [@B3], [@B5], [@B7], [@B9]. Moreover, eight studies completed all diagnostic procedures within 7-14 days [@B3], [@B5]-[@B11]. Seven studies excluded participants with hyperglycemia [@B5]-[@B11]; another seven studies evaluated diagnostic findings of different modalities using double-blind method [@B3], [@B5]-[@B10].

Assessment of study quality
---------------------------

Two investigators showed a good agreement in their assessment of signalling questions, with a *kappa* coefficient of 0.823 (*P* \< 0.001) (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Generally, for patients with negative findings on PET/CT and CWUs, close clinical/imaging follow-up was used as the reference standard. If distant metastases were suspected on PET/CT or CWUs, biopsy was pursued whenever possible. If biopsy was not feasible or yielded negative results, clinical/imaging follow-up was performed. This procedure seems reasonable and appropriate in practice but might subject to differential verification bias. Therefore, for studies regarding both clinical/imaging follow-up and biopsy as reference standard, the answer was "no" for question 2-3 of the flow and timing domain (i.e., did all patients receive the same reference standard). Moreover, no study reported whether or not the clinical/imaging follow-up was interpreted without knowledge of PET/CT or CWUs. Thus, both investigators answered "unclear" for question 2 of the reference standard domain (i.e., were the reference standard results blind to the results of the index test).

The methodological quality summary of all included studies is shown in the Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}. The general quality was fair in terms of risk of bias. All studies had low risk in the index test domain; three studies had low risk in the patient selection domain [@B5], [@B7], [@B9]. Considering unclear blind method in reference standard and differential verification bias among patients, all studies were evaluated as "unclear" in the remaining domains. Owning to the stringent inclusion criteria and consistent population characteristics, the overall quality was good in terms of applicability. Only two study was assessed as "high" in the patient selection domain because of the limitation of sample size [@B3], [@B11]. Thus, seven of ten studies were regarded as high-quality [@B4]-[@B7], [@B9], [@B10], [@B12], of which, three studies had five items that were evaluated as low risk/concern [@B5], [@B7], [@B9].

Diagnostic value of ^18^F-FDG PET/CT
------------------------------------

Nine studies were included in the meta-analysis of ^18^F-FDG PET/CT (1474 patients) [@B3], [@B5]-[@B12]. There was no threshold effect inducing heterogeneity with the Spearman correlation coefficient of -0.261 (*P* = 0.497). Moreover, non-significant heterogeneity was reported in pooled LR- (*P* = 0.632; *I^2^* = 0%), LR+ (*P* = 0.582; *I^2^* = 0%); mild heterogeneity was reported in pooled specificity (*P* = 0.188; *I^2^* = 28.9%) and sensitivity (*P* = 0.061; *I^2^* = 46.3%).

The pooled sensitivity and specificity were 85.7% \[95% confidence interval (CI), 80.1%-90.2%\] and 98.1% (95% CI, 97.2%-98.8%), respectively (Figure [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}B). Likelihood ratio syntheses yielded an overall LR- of 0.180 (95% CI, 0.131-0.248) and LR+ of 35.182 (95% CI, 23.902-51.786) (Figure [2](#F2){ref-type="fig"}C-[2](#F2){ref-type="fig"}D). SROC curve showed an AUC of 0.9812 and Q\* index of 0.9394.

Diagnostic value of CWUs
------------------------

Considering the substantial heterogeneity detected in pooled sensitivity (*P* \< 0.001; *I^2^* = 87.6%) and LR- (*P* \< 0.001; *I^2^* = 80.2%), it was not appropriate to perform pooling analysis for all six studies [@B4]-[@B6], [@B8]-[@B10]. After discarding the only one study with high risk of bias [@B8], five studies (1329 patients) with moderate heterogeneity in pooled sensitivity, specificity, LR+ and LR- (*I^2^* = 46.9%, 71.1%, 61.2%, 41.7%, respectively) were included in the meta-analysis of CWUs [@B4]-[@B6], [@B9], [@B10]. Moreover, no significant heterogeneity due to threshold effect existed since the Spearman correlation coefficient was 0.100 (*P* = 0.873).

The pooled sensitivity and specificity were 38.0% (95% CI, 31.4%-45.0%) and 97.6% (95% CI, 96.5%-98.4%), respectively (Figure [3](#F3){ref-type="fig"}A-[3](#F3){ref-type="fig"}B). Likelihood ratio syntheses yielded an overall LR- of 0.653 (95% CI, 0.562-0.759) and LR+ of 14.748 (95% CI, 6.746-32.245) (Figure [3](#F3){ref-type="fig"}C-[3](#F3){ref-type="fig"}D). SROC curve showed an AUC of 0.9040 and Q\* index of 0.8355.

Head-to-head comparison of ^18^F-FDG PET/CT and CWUs
----------------------------------------------------

Four studies enrolling 1029 patients were included in the head-to-head comparison of diagnostic performance between PET/CT and CWUs (Table [3](#T3){ref-type="table"}) [@B5], [@B6], [@B9], [@B10]. Spearman correlation coefficient was -0.400 (*P* = 0.600) in PET/CT and 0.200 (*P* = 0.800) in CWUs. All pooled outcomes of PET/CT had no significant heterogeneity (all *I^2^*-values = 0%). Moderate heterogeneity was detected for CWUs in pooled sensitivity, LR-, and LR+ (*I^2^* = 54.1%, 53.1%, 64.9%, respectively); marginally substantial heterogeneity was reported in pooled specificity (*I^2^* = 76.5%).

The results showed that PET/CT had a significantly better pooled sensitivity (83.7% vs. 40.1%, *P* \< 0.001) and LR- (0.169 vs. 0.633, *P* \< 0.001) than CWUs. However, no significant difference was observed in pooled specificity (97.7% vs. 97.8%, *P* = 0.892) or LR+ (36.416 vs. 16.845, *P* = 0.149). Moreover, symmetric SROC curves for the diagnostic performance of PET/CT and CWUs were shown in Figure [4](#F4){ref-type="fig"}A-[4](#F4){ref-type="fig"}B; DerSimonian-Laird model was used since the regression coefficient-*b* was -0.008 (*P* = 0.9961) in PET/CT and -0.613 (*P* = 0.4797) in CWUs. The AUC and Q\* index for PET/CT were greater than their counterparts for CWUs (0.9799 vs. 0.9137, *P* = 0.040; 0.9371 vs. 0.8462, *P* = 0.014, respectively).

When the comparisons were among specific sites, PET/CT had a higher pooled sensitivity and LR- than skeletal scintigraphy (89.8% vs. 42.0%, *P* \< 0.001; 0.109 vs. 0.608, *P* \< 0.001, respectively), chest X-ray examination (87.5% vs. 39.3%, *P* \< 0.001; 0.133 vs. 0.670, *P* \< 0.001, respectively) and liver ultrasound (72.7% vs. 35.7%, *P* \< 0.001; 0.310 vs. 0.635, *P* = 0.033, respectively). However, the outcome also indicated relatively poor sensitivity and LR- of PET/CT in the aspect of detection of liver metastasis (72.7% and 0.310, respectively). Significantly improved results in AUC and Q\* index were only observed in the subgroup of PET/CT versus skeletal scintigraphy (*P* = 0.033, 0.009, respectively). Thus, the superiority of PET/CT over CWUs was due mainly to the superb diagnostic performance on bone metastasis. Moreover, the pooled outcomes of PET/CT had generally non-significant heterogeneity, while substantial heterogeneity was observed for chest X-ray examination and liver ultrasound (Table [3](#T3){ref-type="table"}).

Sensitivity analysis and preliminary diagnostic results of other modalities
---------------------------------------------------------------------------

The sensitivity analysis of PET/CT that individually included six studies with high-quality (i.e. ≥ four items of low risk/concern) [@B5]-[@B7], [@B9], [@B10], [@B12], three high-quality studies having five items of low risk/concern [@B5], [@B7], [@B9], and five studies published in English [@B3], [@B5]-[@B7], [@B9], yielded stable outcomes and excellent consistency among included studies; *I^2^*-values of all pooled results were 0% (Table [4](#T4){ref-type="table"}). All pooled sensitivities were similar to each other and lower than the original analysis. The sensitivity analyses of English publications and studies having five items of low risk/concern also showed relatively poor values in LR- of 0.200 and 0.201, respectively. Moreover, compared with the results from two previous meta-analyses, our study showed greater between-study consistency and obviously lower pooled sensitivity [@B21], [@B31]. Because of the limited number of topic-related studies, we only summarized the diagnostic pergormance of other modalities on a per‑patient basis in Table [4](#T4){ref-type="table"}. No significant difference in sensitivity or specificity was reported when each modality was compared with PET/CT in its own study [@B4], [@B5], [@B7], [@B9].

Deeks\' funnel plots were performed to assess potential publication bias. The results indicated symmetric funnel shapes and suggested no significant publication bias for studies using PET/CT (*P* = 0.787) or CWUs (*P* = 0.914) (Figure [5](#F5){ref-type="fig"}).

Discussion
==========

If metastasis is missed during the initial staging, patients with NPC experience unnecessary morbidity and incur the costs of aggressive local-regional radiotherapy while losing the chance of receiving appropriate systemic chemotherapy at an early stage. Thus, the optimal modality to detect metastasis in primary NPC should have high sensitivity, whereby false-negative results can be minimized. The current meta-analysis demonstrated that ^18^F-FDG PET/CT had higher sensitivity for metastasis detection compared to CWUs. Moreover, PET/CT allow simplification of the initial staging evaluation and reduce the anxiety of patients during testing, since it is single procedure as opposed to the multiple procedures involved in CWUs.

However, although PET/CT was superior to CWUs, the pooled sensitivity of PET/CT was not optimal, especially in the aspect of detection of liver metastasis. The sensitivity analysis also showed generally lower values in pooled sensitivities than the original analysis. The following reasons may explain why. First, semi-quantitative evaluation by using standardized uptake value of PET/CT is very prone to variations by technical factors of the scanner system and biological factors of patient [@B32]-[@B34]. Although most of the included studies had restrictions on blood glocose level, time between FDG injection and scanning, and reconstruction method, there were still a lot of factors affecting the sensitivity of PET/CT, such as the partial volume effect, variable physiological uptake, and different acquisition parameters. Second, increasing evidence suggests that metastasis-initiating cells are cancer stem cells that may enter into a protracted period of dormancy before subsequent reactivation and proliferation [@B35]. Therefore, these metastasis-initiating cells might lack increased glucose metabolism and not FDG avid. In the future, technological improvements and standardization of PET/CT imaging procedures can help to further improve its sensitivity for detecting metastasis in primary NPC.

An important concern regarding PET/CT is the high cost, especially in developing countries. In an interesting study, Tang et al. tried to limit the use of PET/CT to patients with a higher-risk of metastasis at presentation in order to reduce costs [@B9]. They divided patients into very low-risk, low-risk, and intermediate-risk groups for metastases based on node classification and pretreatment EBV-DNA levels. They demonstrated that the costs per true-positive case detected by PET/CT were \$47,458, \$14,188, and \$5,005 in the three groups, respectively. Therefore, they did not recommend routine PET/CT in the very low-risk and low-risk groups. However, clinicians should be aware that this study was not a cost-effectiveness study but a cost-minimization study, and the cost analyses did not include the consequences of the imaging tests and associated costs (e.g., the standard therapy for NPC if no distant metastases are detected, type of therapy if metastases are detected on staging, and extra imaging tests and biopsies required for both true- and false-positive results) or the difference in therapeutic effects (e.g., survival). Nonetheless, the selective PET/CT application approach based on appropriate stratification of NPC patients suggested by Tang et al. is appealing and warrants further investigation in future studies.

Our study differs from two previous meta-analyses in the respects shown in supplementary Table [S2](#SM1){ref-type="supplementary-material"} [@B21], [@B31]. Although these meta-analyses reported that PET/CT had good diagnostic performance for metastasis in NPC, they showed relatively poor reliability, mainly because of differences in patient populations (e.g., patients with primary or residual/recurrent disease [@B36], [@B37], all diagnosed patients or patients with negative results on CWUs [@B38]) and the target condition (metastases to all sites or bones only [@B39]) across the studies included. More importantly, these meta-analyses did not compare the diagnostic performance of PET/CT and CWUs. Our study showed obviously lower values in pooled sensitivities and generally greater between-study consistency than the previous meta-analyses. Moreover, we included a large population of 1774 patients through a stringent inclusion and exclusion criteria, which helped to improve the overall reliability.

The present meta-analysis has several limitations that must be taken into account. First, previous studies have reported that the whole-body MRI with diffusion weighted imaging has equivalent diagnostic efficacy for detection of distant metastasis as PET/CT in other malignacies [@B19], [@B40]. However, limited number of topic-related studies on the diagnostic performance of whole-body MRI in NPC prevented us from further investigation. We summarized preliminary results on the diagnostic performance of other modalities, which indicated promising alternatives such as whole-body MRI and CT of thorax and abdomen plus skeletal scintigraphy. However, those crude comparisons can not give an accurate conclusion. Second, the number of included studies was limited, especially for the head-to-head comparison. We excluded studies that enrolled patients with residual/recurrent disease, because previous treatment might influence the diagnostic accuracy of imaging modalities. It was reported that the sensitivity of PET/CT is significantly higher for recurrent NPC than primary disease [@B31]. Third, three included studies published in Chinese reported that the sensitivity and specificity of PET/CT were 100.0% and 100.0% [@B8], [@B11], [@B12]. Such results were too good to be believed. The small sample size was one of the reasons since two studies only involved less than fifty participants [@B11], [@B12]. Although we performed the sensitivity analysis of English publications and obtained stable outcomes, the influence of small sample size may still result into bias for the original analysis.

Conclusion
==========

^18^F-FDG PET/CT were significantly better than CWUs in detecting metastasis in primary NPC during initial staging. However, the efficacy of PET/CT in detecting liver metastasis still needs to be optimized. In the future, studies performing cost-benefit analysis of PET/CT and exploring alternative modalities are needed.
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![Flow chart describing the identification, inclusion and exclusion of studies.](jcav08p1238g001){#F1}

![Forest plots of ^18^F-FDG PET/CT on a per-patient basis in sensitivity (**A**), specificity (**B**), positive likelihood ratio (**C**), and negative likelihood ratio (**D**). CI: confidence interval; LR: likelihood ratio. Circles are the point estimates of studies with the 95% CIs indicated by horizontal bars. The size of the circles indicates the weight of each study. Diamonds are the summary estimates from the pooled studies with the 95% CIs indicated by horizontal bars. All pooled results were slightly different from the results reported in the text because of rounding.](jcav08p1238g002){#F2}

![Forest plots of CWUs on a per-patient basis in sensitivity (**A**), specificity (**B**), positive likelihood ratio (**C**), and negative likelihood ratio (**D**). CI: confidence interval; LR: likelihood ratio. Circles are the point estimates of studies with the 95% CIs indicated by horizontal bars. The size of the circles indicates the weight of each study. Diamonds are the summary estimates from the pooled studies with the 95% CIs indicated by horizontal bars. All pooled results were slightly different from the results reported in the text because of rounding.](jcav08p1238g003){#F3}

![Summary receiver operating characteristic (SROC) curves for the diagnostic performance of ^18^F-FDG PET/CT (**A**) and CWUs (**B**). AUC: area under the curve; SE: standard error. The size of the circles indicates the weight of each study.](jcav08p1238g004){#F4}

![Deeks\' funnel plots of ^18^F-FDG PET/CT (**A**) and CWUs (**B**) to evaluate potential publication bias. ESS: effective sample size. *P* = 0.787 and 0.914 indicate symmetrical funnel shapes and suggest no publication bias.](jcav08p1238g005){#F5}

###### 

Characteristics of ten included studies on the diagnostic performance of ^18^F-FDG PET/CT and CWUs

  First author /year                                Time range   Country or region             Language   Type of design   Patients no. (M/F)   Mean age   Stage (AJCC)   Histologic type (WHO)   Reference standard                       Follow-up time (mo.)   Metastasis prevalence
  ------------------------------------------------- ------------ ----------------------------- ---------- ---------------- -------------------- ---------- -------------- ----------------------- ---------------------------------------- ---------------------- -----------------------
  **^18^F-FDG PET/CT versus CWUs**                                                                                                                                                                                                                                
  Chua/2009 \[5\]                                   2005-2006    Singapore                     English    Prospective      78 (60/18)           50.00      T1-4; N0-3     II-III                  Biopsy, imaging and clinical follow-up   ≥ 6                    7.7%
  Ng/2009 \[6\]                                     NR           Taiwan                        English    Prospective      111 (84/27)          48.90      T1-4; N0-3     NR                      Biopsy, imaging and clinical follow-up   ≥ 12                   14.4%
  Zhang/2011 \[10\]                                 2004-2007    Mainland, China               Chinese    Retrospective    257 (201/56)         45.00      T1-4; N0-3     I-III                   Biopsy, imaging and clinical follow-up   ≥ 36                   15.2%
  Lin/2012^a^ \[8\]                                 2004-2009    Mainland, China               Chinese    Retrospective    216 (168/48)         45.00      T1-4; N0-3     I-III                   Biopsy, imaging and clinical follow-up   NR                     14.8%
  Tang/2013 \[9\]                                   2007-2011    Mainland, China               English    Prospective      583 (474/109)        46.00      T1-4; N0-3     II-III                  Biopsy, imaging and clinical follow-up   ≥ 12                   14.8%
  **^18^F-FDG PET/CT versus other modalities**^b^                                                                                                                                                                                                                 
  Chen/2006 \[3\]                                   2002-2004    Taiwan                        English    Retrospective    20^c^ (14/6)         46.30      T1-4; N0-3     NR                      Biopsy, imaging and clinical follow-up   ≥ 6                    10.0%
  Ng/2009 \[7\]                                     2006-2007    Taiwan                        English    Prospective      150 (111/39)         48.17      T1-4; N0-3     NR                      Biopsy, imaging and clinical follow-up   ≥ 12                   12.0%
  Wang/2007 \[11\]                                  2002-2005    Mainland, China & Australia   Chinese    Retrospective    18^d^ (NR)           52.00      I-IVb          NR                      Biopsy, imaging and clinical follow-up   Median: 17             11.1%
  Lin/2009 \[12\]                                   2004-2008    Mainland, China               Chinese    Retrospective    41 (25/16)           52.30      T1-4; N0-3     II-III                  Biopsy                                   NR                     4.9%
  **CWUs versus ^18^F-FDG PET alone**                                                                                                                                                                                                                             
  Liu/2007 \[4\]                                    2002-2005    Taiwan                        English    Prospective      300 (210/90)         50.00      T1-4; N0-3     II-III                  Biopsy, imaging and clinical follow-up   ≥ 12                   20.3%

Abbreviations: ^18^F-FDG: ^18^F-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography; CWUs: conventional work-ups; AJCC: American Joint Committee on Cancer; WHO: World Health Organization; T: primary tumor stage; N: node stage; M: male; F: female; no.: number; mo.: months; NR: not reported.

^a^The comparison was performed between two matched groups which separately adopted ^18^F-FDG PET/CT and CWUs.

^b^ The study by Chua et al. and Tang et al. also compared ^18^F-FDG PET/CT with other modalities; we omitted them to avoid repetition.

^c^ This study enrolled 70 patients; only the 20 newly diagnosed patients were analysed.

^d^ This study enrolled 43 patients; only the 18 patients diagnosed during the initial staging were analysed.

###### 

Parameters of ^18^F-FDG PET/CT from nine included studies

  First author /year   Type of scanner (corporation)   FDG dose      Time btw FDG injection and scanning (min)   CT slice thickness (mm)   Acquisition mode   Reconstruction method   Criteria defining positive PET/CT result   Interpreters   Design of comparison
  -------------------- ------------------------------- ------------- ------------------------------------------- ------------------------- ------------------ ----------------------- ------------------------------------------ -------------- --------------------------------------------
  Chua/2009 \[5\]      PET/CT (Siemens)                370 MBq       60                                          NR                        NR                 NR                      Semi-quantitive (three-point scale)        1NMP           CWUs; PET alone; CT of thorax & abdomen+SS
  Ng/2009 \[6\]        PET/CT (GE)                     370 MBq       50-70                                       3.00                      2D                 iterative               NR                                         1R+2NMP        CWUs
  Zhang/2011 \[10\]    PET/CT (GE)                     296-440 MBq   45-60                                       4.25                      NR                 iterative               NR                                         1R+1NMP        CWUs
  Lin/2012 \[8\]       PET/CT (NR)                     296-440 MBq   45                                          4.25                      NR                 NR                      NR                                         NR             CWUs^a^
  Tang/2013 \[9\]      PET/CT (GE)                     5.55 MBq/kg   45-60                                       NR                        3D                 iterative               Semi-quantitive (three-point scale)        3NMP           CWUs; PET/CT+CWUs
  Chen/2006 \[3\]      PET/CT (GE)                     370 MBq       50-70                                       4.80                      3D                 iterative               Semi-quantitive (five-point scale)         1R+1NMP        PET alone; CT
  Ng/2009 \[7\]        PET/CT (GE)                     370 MBq       50-70                                       3.00                      2D                 iterative               Semi-quantitive (five-point scale)         1R+1NMP        Whole-body MRI
  Wang/2007 \[11\]     PET/CT (GE)                     270-370 MBq   40-60                                       NR                        3D                 iterative               NR                                         R+NMP^b^       CT+MRI
  Lin/2009 \[12\]      PET/CT (Siemens)                550 MBq       45-60                                       4.25                      NR                 NR                      NR                                         2R+2NMP        MRI

Abbreviations: ^18^F-FDG: ^18^F-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography; CWUs: conventional work-ups; SS: skeletal scintigraphy; MRI: magnetic resonance imaging; btw: between; NA: not applicable; NR: not reported; 3D: three-dimensional; 2D: two-dimensional; R: radiologist; NMP: nuclear medicine physician.

^a^ The comparison was performed between two matched groups which separately adopted ^18^F-FDG PET/CT and CWUs.

^b^ No detailed number of interpreters was reported.

###### 

Head-to-head comparison of the diagnostic performance between ^18^F-FDG PET/CT and CWUs on both patient and site basis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Test                                Sensitivity (%)\   *P*        Specificity (%)\   *P*     LR-\            *P*        LR+\                *P*     AUC      *P*     Q\*      *P*
                                      (95% CI)                      (95% CI)                   (95% CI)                   (95% CI)                                              
  ----------------------------------- ------------------ ---------- ------------------ ------- --------------- ---------- ------------------- ------- -------- ------- -------- -------
  **Patient based \[5, 6, 9, 10\]**                                                                                                                                             

  PET/CT                              83.7\              \< 0.001   97.7\              0.892   0.169\          \< 0.001   36.416\             0.149   0.9799   0.040   0.9371   0.014
                                      (76.7-89.3)                   (96.5-98.6)                (0.117-0.244)              (23.459-56.528)                                       

  *I^2^* (%)                          0.0                           0.0                        0.0                        0.0                         NA               NA       

  CWUs                                40.1\                         97.8\                      0.633\                     16.845\                     0.9137           0.8462   
                                      (32.1-48.5)                   (96.7-98.7)                (0.507-0.790)              (5.960-47.611)                                        

  *I^2^* (%)                          54.1                          76.5                       53.1                       64.9                        NA               NA       

  **Site based \[5, 6, 9, 10\]**                                                                                                                                                

  **Bones**                                                                                                                                                                     

  PET/CT                              89.8\              \< 0.001   98.7\              0.853   0.109\          \< 0.001   59.260\             0.177   0.9907   0.033   0.9603   0.009
                                      (81.5-95.2)                   (97.8-99.3)                (0.060-0.199)              (33.998-103.291)                                      

  *I^2^* (%)                          0.0                           37.4                       0.0                        0.0                         NA               NA       

  SS                                  42.0\                         98.8\                      0.608\                     31.348\                     0.9502           0.8907   
                                      (31.6-53.0)                   (97.9-99.4)                (0.443-0.834)              (16.702-58.837)                                       

  *I^2^* (%)                          64.1                          0.0                        53.6                       0.0                         NA               NA       

  **Lung**                                                                                                                                                                      

  PET/CT                              87.5\              \< 0.001   99.0\              0.117   0.133\          \< 0.001   85.828\             0.799   0.9936   0.275   0.9680   0.170
                                      (75.9-94.8)                   (98.3-99.5)                (0.068-0.260)              (29.236-251.969)                                      

  *I^2^* (%)                          0.0                           17.6                       0.0                        52.2                        NA               NA       

  CXR                                 39.3\                         99.6\                      0.670\                     62.462\                     0.9657           0.9130   
                                      (26.5-53.2)                   (99.0-99.9)                (0.443-1.013)              (13.244-294.581)                                      

  *I^2^* (%)                          81.2                          48.7                       75.9                       39.5                        NA               NA       

  **Liver**                                                                                                                                                                     

  PET/CT                              72.7\              \< 0.001   100.0\             0.381   0.310\          0.033      250.740\            0.684   0.9934   0.483   0.9676   0.404
                                      (57.2-85.0)                   (99.6-100.0)               (0.201-0.478)              (60.354-1043.400)                                     

  *I^2^* (%)                          0.0                           0.0                        0.0                        0.0                         NA               NA       

  US                                  35.7\                         99.8\                      0.635\                     95.839\                     0.9777           0.9329   
                                      (21.6-52.0)                   (99.2-100.0)               (0.424-0.952)              (8.146-1127.500)                                      

  *I^2^* (%)                          55.8                          79.8                       31.2                       63.9                        NA               NA       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ^18^F-FDG: ^18^F-fluorodeoxyglucose; PET: positron emission tomography; CWUs: conventional work-ups; CI: confidence interval; LR-: negative likelihood ratio; LR+: positive likelihood ratio; AUC: area under the curve; SS: skeletal scintigraphy; CXR: chest X-ray examination; US: ultrasound; NA: not applicable.

###### 

Summary of the diagnostic performance of ^18^F-FDG PET/CT and other modalities on a per-patient basis

  Study                                                                       Sensitivity (%) (95% CI)   *I^2^*(%)   Specificity (%) (95% CI)   *I^2^*(%)   LR- (95% CI)          *I^2^*(%)   LR+ (95% CI)             *I^2^*(%)
  --------------------------------------------------------------------------- -------------------------- ----------- -------------------------- ----------- --------------------- ----------- ------------------------ -----------
  **Diagnostic performance of PET/CT from three meta-analyses**                                                                                                                                                        
  Our study                                                                                                                                                                                                            
  All related studies \[3, 5‑12\]                                             85.7 (80.1-90.2)           46.3        98.1 (97.2-98.8)           28.9        0.180 (0.131-0.248)   0.0         35.182 (23.902-51.786)   0.0
  Compared to CWUs \[5, 6, 9, 10\]                                            83.7 (76.7-89.3)           0.0         97.7 (96.5-98.6)           0.0         0.169 (0.117-0.244)   0.0         36.416 (23.459-56.528)   0.0
  High-quality studies (≥ four items) \[5‑7, 9, 10, 12\]                      82.6 (76.0-88.1)           0.0         97.8 (96.7-98.6)           0.0         0.187 (0.135-0.285)   0.0         36.265 (24.150-54.459)   0.0
  High-quality studies (five items) \[5, 7, 9\]                               80.9 (72.3-87.8)           0.0         97.9 (96.5-98.8)           0.0         0.201 (0.137-0.295)   0.0         37.473 (22.500-62.412)   0.0
  English publications \[3, 5‑7, 9\]                                          81.3 (73.4-87.6)           0.0         97.7 (96.4-98.6)           0.0         0.200 (0.140-0.285)   0.0         32.091 (20.517-50.196)   0.0
  Shen et al. \[31\]^a^                                                       89.0 (84.0-93.0)           58.7        97.0 (96.0-98.0)           59.7        NR                    NR          NR                       NR
  Vellayappan et al. \[21\]                                                   87.0 (74.0-100.0)          0.0         98.0 (96.0-100.0)          0.0         NR                    NR          NR                       NR
  **Preliminary results on the diagnostic performance of other modalities**                                                                                                                                            
  CT of thorax and abdomen+SS \[5\]                                           66.7 (30.0-90.3)           \-          91.7 (83.0-96.1)           \-          NR                    \-          NR                       \-
  Whole-body MRI \[7\]                                                        77.8 (52.4-93.6)           \-          98.5 (94.6-99.8)           \-          NR                    \-          NR                       \-
  PET/CT+CWUs \[9\]                                                           83.7 (75.9-91.5)           \-          97.0 (95.5-98.5)           \-          NR                    \-          NR                       \-
  PET alone+CWUs \[4\]                                                        83.6 (NR)                  \-          93.7 (NR)                  \-          NR                    \-          NR                       \-

Abbreviations: ^18^F-FDG: ^18^F-fluorodeoxyglucose; PET: positron emission tomography; CT: computed tomography; CWUs: conventional work-ups; MRI: magnetic resonance imaging; SS: skeletal scintigraphy; CI: confidence interval; LR-: negative likelihood ratio; LR+: positive likelihood ratio; NR: not reported.

^a^Only showed the pooled results of the subgroup of PET/CT which included patients with both newly diagnosed and reccurent disease.
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